Surgical immune interventions for solid malignancies

American Journal of Surgery

Volumn 212, Issue 4, 2016, Pages 682-690.e5

  Zeltsman, Masha ^a   Mayor, Marissa ^a   Jones, David R ^a   Adusumilli, Prasad S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Adoptive cell therapy; Regional immunotherapy; Surgical immunotherapy

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; CANCER VACCINE; CATUMAXOMAB; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; IODINE 131; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; MONOCLONAL ANTIBODY MOV18; ONCOLYTIC VIRUS; PICIBANIL; RECOMBINANT INTERLEUKIN 2; RHENIUM 186; TENASCIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRUS VECTOR; YTTRIUM 90;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CENTRAL NERVOUS SYSTEM METASTASIS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DENDRITIC CELL; DRUG DELIVERY SYSTEM; GASTROINTESTINAL TUMOR; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG CANCER; MACROPHAGE; MALIGNANT ASCITES; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT PLEURA EFFUSION; MELANOMA; METASTASIS; METASTATIC COLON CANCER; MONONUCLEAR CELL; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; OVARY CANCER; OVARY TUMOR; PERITONEAL CARCINOMATOSIS; PERITONEUM CANCER; PERITONEUM MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SOLID TUMOR; STOMACH CANCER; SYSTEMATIC REVIEW; THYROID CANCER; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; CATHETERIZATION; IMMUNOTHERAPY; INTRALESIONAL DRUG ADMINISTRATION; LAPAROSCOPY; NEOPLASMS; PATHOLOGY; PROCEDURES; VASCULAR ACCESS DEVICE;

ANTIBODIES, MONOCLONAL; BCG VACCINE; CATHETERIZATION; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; LAPAROSCOPY; NEOPLASMS; TUMOR MICROENVIRONMENT; VASCULAR ACCESS DEVICES;

EID: 84991661141     PISSN: 00029610     EISSN: 18791883     Source Type: Journal    
DOI: 10.1016/j.amjsurg.2016.06.008     Document Type: Article

References (194)

1. 1 Suzuki, K., Kachala, S.S., Kadota, K., et al. Prognostic immune markers in non-small cell lung cancer. Clin Cancer Res 17 (2011), 5247–5256.
2. 2 Galon, J., Costes, A., Sanchez-Cabo, F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
3. 3 Suzuki, K., Kadota, K., Sima, C.S., et al. Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunol Immunother 60 (2011), 1721–1728.
4. 4 Pages, F., Berger, A., Camus, M., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353 (2005), 2654–2666.
5. 5 Mahmoud, S.M., Paish, E.C., Powe, D.G., et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29 (2011), 1949–1955.
6. 6 Zhang, L., Conejo-Garcia, J.R., Katsaros, D., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348 (2003), 203–213.
7. 7 Nakano, O., Sato, M., Naito, Y., et al. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 61 (2001), 5132–5136.
8. 8 Fukunaga, A., Miyamoto, M., Cho, Y., et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28 (2004), e26–e31.
9. 9 Suzuki, K., Kadota, K., Sima, C.S., et al. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol 31 (2013), 490–498.
10. 10 Kadota, K., Nitadori, J., Ujiie, H., et al. Prognostic impact of immune microenvironment in lung squamous cell carcinoma: tumor-infiltrating CD10+ neutrophil/CD20+ lymphocyte ratio as an independent prognostic factor. J Thorac Oncol 10 (2015), 1301–1310.
11. 11 Rosenberg, S.A., IL-2: the first effective immunotherapy for human cancer. J Immunol 192 (2014), 5451–5458.
12. 12 Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
13. 13 Chiocca, E.A., Rabkin, S.D., Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res 2 (2014), 295–300.
14. 14 Turcotte, S., Gros, A., Hogan, K., et al. Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy. J Immunol 191 (2013), 2217–2225.
15. 15 Klebanoff, C.A., Rosenberg, S.A., Restifo, N.P., Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med 22 (2016), 26–36.
16. 16 Kachala, S.S., Bograd, A.J., Villena-Vargas, J., et al. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma. Clin Cancer Res 20 (2014), 1020–1028.
17. 17 Servais, E.L., Colovos, C., Rodriguez, L., et al. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res 18 (2012), 2478–2489.
18. 18 Adusumilli, P.S., Cherkassky, L., Villena-Vargas, J., et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med, 6, 2014, 261ra151.
19. 19 Millar, J.W., Hunter, A.M., Horne, N.W., Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions. Thorax 35 (1980), 856–858.
20. 20 Kaufmann, M., Stjernsward, J., Zimmermann, A., et al. Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. Ludwig Lung Cancer Study Group. J Thorac Cardiovasc Surg 89 (1985), 842–847.
21. 21 Yasumoto, K., Yaita, H., Ohta, M., et al. Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative lung cancer patients. Cancer Res 45 (1985), 1413–1417.
22. 22 Lee, Y.C., Luh, S.P., Wu, R.M., et al. Adjuvant immunotherapy with intrapleural Streptococcus pyogenes (OK-432) in lung cancer patients after resection. Cancer Immunol Immunother 39 (1994), 269–274.
23. 23 Bakker, W., Nijhuis-Heddes, J.M., van der Velde, E.A., Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report. Cancer Immunol Immunother 22 (1986), 155–159.
24. 24 Macchiarini, P., Mussi, A., Angeletti, C.A., Intrapleural BCG in postsurgical stage I non-small cell lung cancer. Anticancer Res 9 (1989), 391–393.
25. 25 Astoul, P., Picat-Joossen, D., Viallat, J.R., et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 83 (1998), 2099–2104.
26. 26 Adusumilli, P.S., Stiles, B.M., Chan, M.K., et al. Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. J Gene Med 8 (2006), 603–615.
27. 27 Bennett, J.J., Adusumilli, P., Petrowsky, H., et al. Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J 18 (2004), 1001–1003.
28. 28 Boiardi, A., Bartolomei, M., Silvani, A., et al. Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. J Neuro-oncol 72 (2005), 125–131.
29. 29 Hayes, R.L., Arbit, E., Odaimi, M., et al. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit Rev Oncol Hematol 39 (2001), 31–42.
30. 30 Barba, D., Saris, S.C., Holder, C., et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70 (1989), 175–182.
31. 31 Blancher, A., Roubinet, F., Grancher, A.S., et al. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells. Eur Cytokine Netw 4 (1993), 331–341.
32. 32 Boiardi, A., Silvani, A., Ruffini, P.A., et al. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother 39 (1994), 193–197.
33. 33 Canevari, S., Stoter, G., Arienti, F., et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87 (1995), 1463–1469.
34. 34 Hird, V., Maraveyas, A., Snook, D., et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 68 (1993), 403–406.
35. 35 Kosmas, C., Maraveyas, A., Gooden, C.S., et al. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy. J Nucl Med 36 (1995), 746–753.
36. 36 Rosenblum, M.G., Verschraegen, C.F., Murray, J.L., et al. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res 5 (1999), 953–961.
37. 37 Alvarez, R.D., Huh, W.K., Khazaeli, M.B., et al. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 8 (2002), 2806–2811.
38. 38 Oei, A.L., Massuger, L.F., Oyen, W.J., Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer. Cancer Biother Radiopharm 22 (2007), 508–514.
39. 39 Muto, M.G., Finkler, N.J., Kassis, A.I., et al. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. Gynecol Oncol 45 (1992), 265–272.
40. 40 Riva, P., Tison, V., Arista, A., et al. Radioimmunotherapy of gastrointestinal cancer and glioblastomas. Int J Biol Markers 8 (1993), 192–197.
41. 41 Mahe, M.A., Fumoleau, P., Fabbro, M., et al. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res 5:10 Suppl (1999), 3249s–3253s.
42. 42 Jacobs, A.J., Fer, M., Su, F.M., et al. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obstet Gynecol 82:4 Pt 1 (1993), 586–593.
43. 43 Alvarez, R.D., Partridge, E.E., Khazaeli, M.B., et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 65 (1997), 94–101.
44. 44 Andersson, H., Cederkrantz, E., Back, T., et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2—a phase I study. J Nucl Med 50 (2009), 1153–1160.
45. 45 Maraveyas, A., Snook, D., Hird, V., et al. Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer 73:3 Suppl (1994), 1067–1075.
46. 46 Heiss, M.M., Murawa, P., Koralewski, P., et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127 (2010), 2209–2221.
47. 47 Atanackovic, D., Reinhard, H., Meyer, S., et al. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Hum Vaccines Immunotherapeutics 9 (2013), 2533–2542.
48. 48 Goere, D., Gras-Chaput, N., Auperin, A., et al. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer, 14, 2014, 148.
49. 49 Wright, S.E., Rewers-Felkins, K.A., Quinlin, I.S., et al. Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother 35 (2012), 196–204.
50. 50 Wada, I., Matsushita, H., Noji, S., et al. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med 3 (2014), 362–375.
51. 51 Danielli, R., Patuzzo, R., Di Giacomo, A.M., et al. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother 64 (2015), 999–1009.
52. 52 Berinstein, N.L., Wolf, G.T., Naylor, P.H., et al. Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother 61 (2012), 771–782.
53. 53 Timar, J., Ladanyi, A., Forster-Horvath, C., et al. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial. J Clin Oncol 23 (2005), 3421–3432.
54. 54 Heinzerling, L., Burg, G., Dummer, R., et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 16 (2005), 35–48.
55. 55 Mahvi, D.M., Henry, M.B., Albertini, M.R., et al. Intratumoral injection of IL-12 plasmid DNA–results of a phase I/IB clinical trial. Cancer Gene Ther 14 (2007), 717–723.
56. 56 Dummer, R., Eichmuller, S., Gellrich, S., et al. Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Mol Ther 18 (2010), 1244–1247.
57. 57 Khammari, A., Nguyen, J.M., Saint-Jean, M., et al. Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-gamma) in metastatic melanoma patients. Cancer Immunol Immunother 64 (2015), 805–815.
58. 58 Aguilar, L.K., Shirley, L.A., Chung, V.M., et al. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Cancer Immunol Immunother 64 (2015), 727–736.
59. 59 Heo, J., Reid, T., Ruo, L., et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19 (2013), 329–336.
60. 60 Takeda, T., Kobayashi, T., Monden, T., et al. The effect of local immunotherapy for breast cancer using a mixture of OK-432 and fibrinogen supplemented with activated macrophages. Biotherapy 7 (1993), 47–54.
61. 61 Victora, G.D., Socorro-Silva, A., Volsi, E.C., et al. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients. Cancer Gene Ther 16 (2009), 598–608.
62. 62 Vogl, S.E., Schoenfeld, D.A., Kaplan, B.H., et al. Methotrexate alone or with regional subcutaneous Corynebacterium parvum in the treatment of recurrent and metastatic squamous cancer of the head and neck. Cancer 50 (1982), 2295–2300.
63. 63 Gochi, A., Orita, K., Fuchimoto, S., et al. The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients. Br J Cancer 84 (2001), 443–451.
64. 64 Tanaka, N., Gouchi, A., Ohara, T., et al. Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A randomized trial. Cooperative Study Group of Preoperative Intratumoral Immunotherapy for Cancer. Cancer 74 (1994), 3097–3103.
65. 65 Chi, K.H., Liu, S.J., Li, C.P., et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 28 (2005), 129–135.
66. 66 Duval, L., Schmidt, H., Kaltoft, K., et al. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin Cancer Res 12 (2006), 1229–1236.
67. 67 Fujiwara, S., Wada, H., Miyata, H., et al. Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. J Immunother 35 (2012), 513–521.
68. 68 van Schalkwyk, M.C., Papa, S.E., Jeannon, J.P., et al. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum Gene Ther Clin Dev 24 (2013), 134–142.
69. 69 Cornett, W.R., McCall, L.M., Petersen, R.P., et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 24 (2006), 4196–4201.
70. 70 Papadia, F., Basso, V., Patuzzo, R., et al. Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma. J Surg Oncol 107 (2013), 173–179.
71. 71 Hennemann, B., Scheibenbogen, C., Schumichen, C., et al. Intrahepatic adoptive immunotherapy with autologous tumorcytotoxic macrophages in patients with cancer. J Immunother Emphasis Tumor Immunol 18 (1995), 19–27.
72. 72 Keilholz, U., Scheibenbogen, C., Brado, M., et al. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. Eur J Cancer 30A (1994), 103–105.
73. 73 Zeng, Z.C., Tang, Z.Y., Liu, K.D., et al. Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I/II clinical trials. J Cancer Res Clin Oncol 124 (1998), 275–280.
74. 74 Zeng, Z.C., Tang, Z.Y., Xie, H., et al. Radioimmunotherapy for unresectable hepatocellular carcinoma using 131I-Hepama-1 mAb: preliminary results. J Cancer Res Clin Oncol 119 (1993), 257–259.
75. 75 Melichar, B., Touskova, M., Blaha, M., et al. Hepatic arterial administration of activated leukocytes in patients with liver metastases. Cancer Biother Radiopharm 17 (2002 Oct), 545–552.
76. 76 Gandhi, S.J., Minn, A.J., Vonderheide, R.H., et al. Awakening the immune system with radiation: optimal dose and fractionation. Cancer Lett 368 (2015), 185–190.
77. 77 Twyman-Saint Victor, C., Rech, A.J., Maity, A., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377.
78. 78 Wolchok, J.D., Hoos, A., O'Day, S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
79. 1 Bakker, W., Nijhuis-Heddes, J.M., van der Velde, E.A., Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report. Cancer Immunol Immunother 22 (1986), 155–159.
80. 2 Macchiarini, P., Mussi, A., Angeletti, C.A., Intrapleural BCG in postsurgical stage I non-small cell lung cancer. Anticancer Res 9 (1989), 391–393.
81. 3 Holmes, E.C., Hill, L.D., Gail, M., A randomized comparison of the effects of adjuvant therapy on resected stages II and III non-small cell carcinoma of the lung. The Lung Cancel Study Group. Ann Surg 202 (1985), 335–341.
82. 4 Roeslin, N., Lang, J.M., Morand, G., et al. Regional immunotherapy in resectable squamous cell lung carcinoma. Analysis of a randomized study. Cancer Immunol Immunother 13 (1982), 174–175.
83. 5 McKneally, M.F., Maver, C., Lininger, L., et al. Four-year follow-up on the Albany experience with intrapleural BCG in lung cancer. J Thorac Cardiovasc Surg 81 (1981), 485–492.
84. 6 Jansen, H.M., The, T.H., Orie, N.G., Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma. Thorax 35 (1980), 781–787.
85. 7 Astoul, P., Picat-Joossen, D., Viallat, J.R., et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 83 (1998), 2099–2104.
86. 8 Astoul, P., Viallat, J.R., Laurent, J.C., et al. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 103 (1993), 209–213.
87. 9 Castagneto, B., Zai, S., Mutti, L., et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients. Lung Cancer 31 (2001), 303–310.
88. 10 Goey, S.H., Eggermont, A.M., Punt, C.J., et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 72 (1995), 1283–1288.
89. 11 Viallat, J.R., Boutin, C., Rey, F., et al. Intrapleural immunotherapy with escalating doses of interleukin-2 in metastatic pleural effusions. Cancer 71 (1993), 4067–4071.
90. 12 Millar, J.W., Hunter, A.M., Horne, N.W., Intrapleural immunotherapy with Corynebacterium parvum in recurrent malignant pleural effusions. Thorax 35 (1980), 856–858.
91. 13 Adverse effect of intrapleural Corynebacterium parvum as adjuvant therapy in resected stage I and II non-small cell carcinoma of the lung. Ludwig Lung Cancer Study Group. J Thorac Cardiovasc Surg 89 (1985), 842–847.
92. 14 Yasumoto, K., Yaita, H., Ohta, M., et al. Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative lung cancer patients. Cancer Res 45 (1985), 1413–1417.
93. 15 Lee, Y.C., Luh, S.P., Wu, R.M., et al. Adjuvant immunotherapy with intrapleural Streptococcus pyogenes (OK-432) in lung cancer patients after resection. Cancer Immunol Immunother 39 (1994), 269–274.
94. 16 Monnet, I., Breau, J.L., Moro, D., et al. Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study. Chest 121 (2002), 1921–1927.
95. 17 Yu, L., Ju, D.W., Chen, W., et al. 131I-chTNT radioimmunotherapy of 43 patients with advanced lung cancer. Cancer Biother Radiopharm 21 (2006), 5–14.
96. 18 Boiardi, A., Bartolomei, M., Silvani, A., et al. Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma. J Neurooncol 72 (2005), 125–131.
97. 19 Riva, P., Arista, A., Franceschi, G., et al. Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res 55 (1995), 5952s–5956s.
98. 20 Bigner, D.D., Brown, M., Coleman, R.E., et al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2–a preliminary report. J Neurooncol 24 (1995), 109–122.
99. 21 Brown, M.T., Coleman, R.E., Friedman, A.H., et al. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clin Cancer Res 2 (1996), 963–972.
100. 22 Kramer, K., Cheung, N.K., Humm, J.L., et al. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8. Med Pediatr Oncol 35 (2000), 716–718.
101. 23 Sampson, J.H., Akabani, G., Friedman, A.H., et al. Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies. Neurosurg Focus, 20, 2006, E14.
102. 24 Kramer, K., Humm, J.L., Souweidane, M.M., et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol 25 (2007), 5465–5470.
103. 25 Hayes, R.L., Arbit, E., Odaimi, M., et al. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit Rev Oncol Hematol 39 (2001), 31–42.
104. 26 Barba, D., Saris, S.C., Holder, C., et al. Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70 (1989), 175–182.
105. 27 Blancher, A., Roubinet, F., Grancher, A.S., et al. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells. Eur Cytokine Netw 4 (1993), 331–341.
106. 28 Boiardi, A., Silvani, A., Ruffini, P.A., et al. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother 39 (1994), 193–197.
107. 29 Sankhla, S.K., Nadkarni, J.S., Bhagwati, S.N., Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors. J Neurooncol 27 (1996), 133–140.
108. 30 Rosener, M., Schwulera, U., Menke, G., et al. Tolerance and cerebrospinal fluid pharmacokinetics of intrathecally administered human natural interleukin-2: a phase I trial. Eur Cytokine Netw 4 (1993), 189–195.
109. 31 Salmaggi, A., Dufour, A., Silvani, A., et al. Intrathecal immunotherapy in CNS tumors disseminating via CSF: preliminary evaluation using different treatment schedules. Ital J Neurol Sci 17 (1996), 267–276.
110. 32 Oshiro, S., Tsugu, H., Komatsu, F., et al. Evaluation of intratumoral administration of tumor necrosis factor-alpha in patients with malignant glioma. Anticancer Res 26 (2006), 4027–4032.
111. 33 Yamanaka, R., Homma, J., Yajima, N., et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11 (2005), 4160–4167.
112. 34 Steinbok, P., Thomas, J.P., Grossman, L., et al. Intratumoral autologous mononuclear cells in the treatment of recurrent glioblastoma multiforme. A phase 1 (toxicity) study. J Neurooncol 2 (1984), 147–151.
113. 35 Hird, V., Maraveyas, A., Snook, D., et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 68 (1993), 403–406.
114. 36 Kosmas, C., Maraveyas, A., Gooden, C.S., et al. Anti-chelate antibodies after intraperitoneal yttrium-90-labeled monoclonal antibody immunoconjugates for ovarian cancer therapy. J Nucl Med 36 (1995), 746–753.
115. 37 Rosenblum, M.G., Verschraegen, C.F., Murray, J.L., et al. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. Clin Cancer Res 5 (1999), 953–961.
116. 38 Alvarez, R.D., Huh, W.K., Khazaeli, M.B., et al. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res 8 (2002), 2806–2811.
117. 39 Oei, A.L., Massuger, L.F., Oyen, W.J., Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer. Cancer Biother Radiopharm 22 (2007), 508–514.
118. 40 Muto, M.G., Finkler, N.J., Kassis, A.I., et al. Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. Gynecol Oncol 45 (1992), 265–272.
119. 41 Riva, P., Tison, V., Arista, A., et al. Radioimmunotherapy of gastrointestinal cancer and glioblastomas. Int J Biol Markers 8 (1993), 192–197.
120. 42 Mahe, M.A., Fumoleau, P., Fabbro, M., et al. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res 5 (1999), 3249s–3253s.
121. 43 Jacobs, A.J., Fer, M., Su, F.M., et al. A phase I trial of a rhenium 186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: toxicity and clinical response. Obstet Gynecol 82 (1993), 586–593.
122. 44 Alvarez, R.D., Partridge, E.E., Khazaeli, M.B., et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 65 (1997), 94–101.
123. 45 Andersson, H., Cederkrantz, E., Back, T., et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2—a phase I study. J Nucl Med 50 (2009), 1153–1160.
124. 46 Maraveyas, A., Snook, D., Hird, V., et al. Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. Cancer 73 (1994), 1067–1075.
125. 47 Oei, A.L., Moreno, M., Verheijen, R.H., et al. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. Int J Cancer 123 (2008), 1848–1853.
126. 48 Meredith, R.F., Alvarez, R.D., Partridge, E.E., et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. Cancer Biother Radiopharm 16 (2001), 305–315.
127. 49 Canevari, S., Stoter, G., Arienti, F., et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 87 (1995), 1463–1469.
128. 50 Wright, S.E., Rewers-Felkins, K.A., Quinlin, I.S., et al. Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study. J Immunother 35 (2012), 196–204.
129. 51 Wada, I., Matsushita, H., Noji, S., et al. Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med 3 (2014), 362–375.
130. 52 Canevari, S., Mezzanzanica, D., Mazzoni, A., et al. Bispecific antibody targeted T cell therapy of ovarian cancer: clinical results and future directions. J Hematother 4 (1995), 423–427.
131. 53 Dobrzanski, M.J., Rewers-Felkins, K.A., Samad, K.A., et al. Immunotherapy with IL-10- and IFN-gamma-producing CD4 effector cells modulate “natural” and “inducible” CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer. Cancer Immunol Immunother 61 (2012), 839–854.
132. 54 Lamers, C.H., Gratama, J.W., Warnaar, S.O., et al. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes. Int J Cancer 60 (1995), 450–457.
133. 55 Bolhuis, R.L., Lamers, C.H., Goey, S.H., et al. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer Suppl 7 (1992), 78–81.
134. 56 Heiss, M.M., Murawa, P., Koralewski, P., et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 127 (2010), 2209–2221.
135. 57 Atanackovic, D., Reinhard, H., Meyer, S., et al. The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Hum Vaccin Immunother 9 (2013), 2533–2542.
136. 58 Goere, D., Gras-Chaput, N., Auperin, A., et al. Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer, 14, 2014, 148.
137. 59 Strohlein, M.A., Lordick, F., Ruttinger, D., et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie 34 (2011), 101–108.
138. 60 van Zanten-Przybysz, I., Molthoff, C.F., Roos, J.C., et al. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. Int J Cancer 92 (2001), 106–114.
139. 61 Hesdorffer, M.E., Chabot, J.A., Keohan, M.L., et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol 31 (2008), 49–54.
140. 62 Fu, Q.G., Meng, F.D., Shen, X.D., et al. Efficacy of intraperitoneal thermochemotherapy and immunotherapy in intraperitoneal recurrence after gastrointestinal cancer resection. World J Gastroenterol 8 (2002), 1019–1022.
141. 63 Sartori, S., Nielsen, I., Tassinari, D., et al. Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study. Oncology 61 (2001), 192–196.
142. 64 Frasci, G., Iaffaioli, R.V., Comella, G., et al. Intraperitoneal adjuvant immunochemotherapy in operable gastric cancer with serosal involvement. Clin Oncol 6 (1994), 364–370.
143. 65 Toner, G.C., Gabrilove, J.L., Gordon, M., et al. Phase I trial of intravenous and intraperitoneal administration of granulocyte-macrophage colony-stimulating factor. J Immunother Emphasis Tumor Immunol 15 (1994), 59–66.
144. 66 Freedman, R.S., Kudelka, A.P., Kavanagh, J.J., et al. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res 6 (2000), 2268–2278.
145. 67 Freedman, R.S., Edwards, C.L., Kavanagh, J.J., et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother Emphasis Tumor Immunol 16 (1994), 198–210.
146. 68 Stewart, J.A., Belinson, J.L., Moore, A.L., et al. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 50 (1990), 6302–6310.
147. 69 Lygidakis, N.J., Kosmidis, P., Ziras, N., et al. Combined transarterial targeting locoregional immunotherapy-chemotherapy for patients with unresectable hepatocellular carcinoma: a new alternative for an old problem. J Interferon Cytokine Res 15 (1995), 467–472.
148. 70 Lygidakis, N.J., Pothoulakis, J., Konstantinidou, A.E., et al. Hepatocellular carcinoma: surgical resection versus surgical resection combined with pre- and post-operative locoregional immunotherapy-chemotherapy. A prospective randomized study. Anticancer Res 15 (1995), 543–550.
149. 71 Lygidakis, N.J., Sgourakis, G., Vlachos, L., et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology 48 (2001), 1685–1691.
150. 72 Lygidakis, N.J., Ziras, N., Parissis, J., Resection versus resection combined with adjuvant pre- and post-operative chemotherapy–immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology 42 (1995), 155–161.
151. 73 Chi, K.H., Liu, S.J., Li, C.P., et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 28 (2005), 129–135.
152. 74 Hennemann, B., Scheibenbogen, C., Schumichen, C., et al. Intrahepatic adoptive immunotherapy with autologous tumorcytotoxic macrophages in patients with cancer. J Immunother Emphasis Tumor Immunol 18 (1995), 19–27.
153. 75 Melichar, B., Touskova, M., Blaha, M., et al. Hepatic arterial administration of activated leukocytes in patients with liver metastases. Cancer Biother Radiopharm 17 (2002), 545–552.
154. 76 Hennemann, B., Scheibenbogen, C., Andreesen, R., Biological response to intrahepatic adoptive immunotherapy with autologous interferon activated macrophages. Eur J Cancer, 31A, 1995, 852.
155. 77 Heo, J., Reid, T., Ruo, L., et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19 (2013), 329–336.
156. 78 Abei, M., Okumura, T., Fukuda, K., et al. A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma. Radiat Oncol, 8, 2013, 239.
157. 79 Zeng, Z.C., Tang, Z.Y., Liu, K.D., et al. Improved long-term survival for unresectable hepatocellular carcinoma (HCC) with a combination of surgery and intrahepatic arterial infusion of 131I-anti-HCC mAb. Phase I/II clinical trials. J Cancer Res Clin Oncol 124 (1998), 275–280.
158. 80 Zeng, Z.C., Tang, Z.Y., Xie, H., et al. Radioimmunotherapy for unresectable hepatocellular carcinoma using 131I-Hepama-1 mAb: preliminary results. J Cancer Res Clin Oncol 119 (1993), 257–259.
159. 81 Keilholz, U., Scheibenbogen, C., Brado, M., et al. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. Eur J Cancer 30A (1994), 103–105.
160. 82 Danielli, R., Patuzzo, R., Di Giacomo, A.M., et al. Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. Cancer Immunol Immunother 64 (2015), 999–1009.
161. 83 Berinstein, N.L., Wolf, G.T., Naylor, P.H., et al. Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunol Immunother 61 (2012), 771–782.
162. 84 Heinzerling, L., Burg, G., Dummer, R., et al. Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 16 (2005), 35–48.
163. 85 Mahvi, D.M., Henry, M.B., Albertini, M.R., et al. Intratumoral injection of IL-12 plasmid DNA–results of a phase I/IB clinical trial. Cancer Gene Ther 14 (2007), 717–723.
164. 86 Whalen, G.F., Sullivan, M., Piperdi, B., et al. Cancer immunotherapy by intratumoral injection of alpha-gal glycolipids. Anticancer Res 32 (2012), 3861–3868.
165. 87 O'Malley, B.W. Jr., Li, D., McQuone, S.J., et al. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside. Laryngoscope 115 (2005), 391–404.
166. 88 Rochlitz, C., Dreno, B., Jantscheff, P., et al. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther 9 (2002), 289–295.
167. 89 Galanis, E., Burch, P.A., Richardson, R.L., et al. Intratumoral administration of a 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. Cancer 101 (2004), 2557–2566.
168. 90 Kaufman, H.L., Kim, D.W., DeRaffele, G., et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol 17 (2010), 718–730.
169. 91 Lygidakis, N.J., Sgourakis, G., Georgia, D., et al. Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study. Ann Surg 236 (2002), 806–813.
170. 92 Dummer, R., Eichmuller, S., Gellrich, S., et al. Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Mol Ther 18 (2010), 1244–1247.
171. 93 Aguilar, L.K., Shirley, L.A., Chung, V.M., et al. Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma. Cancer Immunol Immunother 64 (2015), 727–736.
172. 94 Dummer, R., Hassel, J.C., Fellenberg, F., et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 104 (2004), 1631–1638.
173. 95 Hofbauer, G.F., Baur, T., Bonnet, M.C., et al. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate. Melanoma Res 18 (2008), 104–111.
174. 96 Kaufman, H.L., Cohen, S., Cheung, K., et al. Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors. Hum Gene Ther 17 (2006), 239–244.
175. 97 Cripe, T.P., Ngo, M.C., Geller, J.I., et al. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther 23 (2015), 602–608.
176. 98 Gomella, L.G., Mastrangelo, M.J., McCue, P.A., et al. Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer. J Urol 166 (2001), 1291–1295.
177. 99 Khorana, A.A., Rosenblatt, J.D., Sahasrabudhe, D.M., et al. A phase I trial of immunotherapy with intratumoral adenovirus-interferon-gamma (TG1041) in patients with malignant melanoma. Cancer Gene Ther 10 (2003), 251–259.
178. 100 Griscelli, F., Opolon, P., Saulnier, P., et al. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients. Gene Ther 10 (2003), 386–395.
179. 101 Kaufman, H.L., Deraffele, G., Mitcham, J., et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 115 (2005), 1903–1912.
180. 102 Vogl, S.E., Schoenfeld, D.A., Kaplan, B.H., et al. Methotrexate alone or with regional subcutaneous Corynebacterium parvum in the treatment of recurrent and metastatic squamous cancer of the head and neck. Cancer 50 (1982), 2295–2300.
181. 103 Gochi, A., Orita, K., Fuchimoto, S., et al. The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients. Br J Cancer 84 (2001), 443–451.
182. 104 Tanaka, N., Gouchi, A., Ohara, T., et al. Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A randomized trial. Cooperative Study Group of Preoperative Intratumoral Immunotherapy for Cancer. Cancer 74 (1994), 3097–3103.
183. 105 Neifeld, J.P., Terz, J.J., Kaplan, A.M., et al. Adjuvant Corynebacterium parvum immunotherapy for squamous cell epitheliomas of the oral cavity, pharynx, and larynx. J Surg Oncol 28 (1985), 137–145.
184. 106 Amano, M., Sekimoto, M., Monden, T., et al. Selective augmentations of intratumoral 5-fluorouracil concentration by local immunotherapy with OK-432 and fibrinogen. Dis Colon Rectum 43 (2000), 402–407.
185. 107 Duval, L., Schmidt, H., Kaltoft, K., et al. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma. Clin Cancer Res 12 (2006), 1229–1236.
186. 108 Fujiwara, S., Wada, H., Miyata, H., et al. Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. J Immunother 35 (2012), 513–521.
187. 109 van Schalkwyk, M.C., Papa, S.E., Jeannon, J.P., et al. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum Gene Ther Clin Dev 24 (2013), 134–142.
188. 110 Triozzi, P.L., Khurram, R., Aldrich, W.A., et al. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 89 (2000), 2646–2654.
189. 111 Timar, J., Ladanyi, A., Forster-Horvath, C., et al. Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial. J Clin Oncol 23 (2005), 3421–3432.
190. 112 Khammari, A., Nguyen, J.M., Saint-Jean, M., et al. Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-gamma) in metastatic melanoma patients. Cancer Immunol Immunother 64 (2015), 805–815.
191. 113 Takeda, T., Kobayashi, T., Monden, T., et al. The effect of local immunotherapy for breast cancer using a mixture of OK-432 and fibrinogen supplemented with activated macrophages. Biotherapy 7 (1993), 47–54.
192. 114 Victora, G.D., Socorro-Silva, A., Volsi, E.C., et al. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients. Cancer Gene Ther 16 (2009), 598–608.
193. 115 Audia, S., Nicolas, A., Cathelin, D., et al. Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes. Clin Exp Immunol 150 (2007), 523–530.
194. 116 Ariyan, S., Kirkwood, J.M., Mitchell, M.S., et al. Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities. Surgery 92 (1982), 459–463.